In view of possible improvements in ADSC homing to glioma lesions (e.g., by exploring overexpression of the chemokine receptor CXCR4 and the presence of its ligand CXCL12 in glioma lesions), as well as likely additional arming of the myxoma construct with novel therapeutic transgenes, the studied platform could be developed into a powerful tool for a non-invasive approach to destroying glioma lesions. This evidence concerns the gene CXCR4 and glioma.